Abstract 171P
Background
To investigate the effect of both prostate volume and serum testosterone changes on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy.
Methods
A total of 167 patients who received androgen deprivation therapy for prostate cancer treatment from January 2010 to August 2020 were enrolled in this retrospective study. Changes in the International Prostate Symptom Score (IPSS) in the patient groups stratified by prostate volume and the amount of testosterone reduction were assessed every 4 weeks until 12 weeks after androgen deprivation therapy initiation. Longitudinal mixed models were used to assess the adjusted effects of prostate volume and testosterone reduction on IPSS change.
Results
All mean values of IPSS-total score (IPSS-total), voiding subscore (IPSS-vs), and storage subscore (IPSS-ss) significantly decreased from baseline to week 12 in both patients with small (<33 mL) and large (≥33 mL) prostates. The mean values of IPSS-total, IPSS-vs, and IPSS-ss similarly decreased in patients with large prostate with a baseline IPSS-total of ≥13. However, in those with small prostate, IPSS-ss specifically remained unchanged, while IPSS-total and IPSS-vs significantly decreased. In addition, only in patients with small prostate (<33 mL), patients with lesser testosterone reduction (<Δ400 ng/dL) showed greater improvement in IPSS-ss by 6.3% compared with those with greater testosterone reduction (≥ Δ400 ng/dL).
Conclusions
Although androgen deprivation therapy generally improves lower urinary tract symptoms, it may not improve storage symptoms in patients with relatively small prostate and greater testosterone reduction. Our finding suggests that testosterone may influence lower urinary tract symptoms in these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
237P - Dosimetric effects of conscious sparing of contralateral lobe of thyroid gland in select head and neck patients receiving intensity modulated radiotherapy to ipsilateral neck
Presenter: Manish Chomal
Session: Poster viewing 03
238P - Proposing a predictive nomogram for lymph-node metastasis (LNM) in oral squamous cell carcinoma (OSCC) using immunohistochemical marker D2-40
Presenter: Karen Boaz
Session: Poster viewing 03
239P - Prospective evaluation of difference in patient-reported swallowing outcomes and quality of life of tongue vs bucco-alveolar complex cancers treated with ablative surgery
Presenter: Abhinav Thaduri
Session: Poster viewing 03
240P - SERPINE2 promotes the growth, invasion, and metastasis in oral squamous cell carcinoma and is associated with poor prognosis
Presenter: Hao-Wen Chuang
Session: Poster viewing 03
241P - P16 IHC stain is an useful marker for predicting outcome of oropharyngeal cancer in Taiwan
Presenter: chiencheh chen
Session: Poster viewing 03
242P - Epidemiology and survival analysis of head and neck cancer: Results from a comprehensive care center in North India
Presenter: Amit Badola
Session: Poster viewing 03
243P - Induction bio-chemotherapy or bio-chemoimmunotherapy for locally advanced betel-nut-related HNSCC in Taiwan
Presenter: Jo Pai Chen
Session: Poster viewing 03
244P - Alternate-day hypofractionated radiotherapy for radical treatment of head & neck cancer during the COVID-19 pandemic: A single institute experience
Presenter: Pragya Singh
Session: Poster viewing 03
246P - Clinicoepidemiological profile and patterns of failure in carcinoma oral cavity in Indian patients: A 6-year retrospective study
Presenter: Aashita -
Session: Poster viewing 03